Hongyan Li

Director of Oncology at Melior Discovery

Dr. Li has over 30 years of experience in pharmacology. She authored 5 patents and over 50 peer-reviewed publications. She specializes in pre-clinical studies of anticancer therapies and diabetic complications prevention, focusing on pharmacodynamics, pharmacokinetics, and general pharmacological tests.

Prior to joining Melior Discovery in April 2022, Dr. Li was responsible for managing the Radiation Oncology Department and Antitumor Assessment Core Facility at Memorial Sloan-Kettering Cancer Center for over 8 years. She focused on radiation-induced immune response as well as establishing PDX (patient derived xenograft) models and orthotopic xenograft models.

Location

New York, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Melior Discovery

Melior Discovery Inc (Exton, PA, USA) has pioneered a unique “high throughput” in vivo pharmacology platform (theraTRACE®) able to systematically identify novel indications for pre-clinical and development-stage drugs.


Industries

Employees

11-50

Links